View More Recent Stories
-
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
-
Tharimmune (THAR) Files for 1M Share Offering by Selling Stockholders
-
Tharimmune (THAR) Appoints Jules Haimovitz as Key Strategic Advisor
-
Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
-
Tharimmune (THAR) Announces 660K Share Offering at $3.16/sh
-
Tharimmune Announces $2.08 Million Private Placement
-
Tharimmune Announces $2.08 Million Private Placement
-
Tharimmune Announces $2.08 Million Private Placement
-
Tharimmune (THAR) Reports Positive Type C Meeting with FDA for Phase 2 Program for TH104
-
Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
-
Tharimmune (THAR) Reports Positive Results of Phase 1 Trial in Healthy Subjects with TH104
-
Tharimmune (THAR) Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
-
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
-
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
-
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
-
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
-
Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
